| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (NCT05172258) | National Cancer Institute (NCI) | 2022-07-26 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer (NCT04576091) | National Cancer Institute (NCI) | 2022-07-06 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT04862650) | Marcelo Bonomi | 2021-11-30 |
| Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (NCT04643379) | Washington University School of Medicine | 2021-08-07 |
| Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC (NCT05156970) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2021-06-24 |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (NCT04671667) | National Cancer Institute (NCI) | 2021-04-27 |
| NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer (NCT04862455) | M.D. Anderson Cancer Center | 2021-04-07 |
| NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery (NCT04588038) | Hyunseok Kang, MD | 2021-03-12 |
| Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer (NCT04834349) | M.D. Anderson Cancer Center | 2021-03-09 |
| Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition (NCT04454489) | Wake Forest University Health Sciences | 2021-02-25 |
| An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (NCT04305795) | Rakuten Medical, Inc. | 2020-12-21 |
| CIML NK Cell in Head & Neck Cancer (NCT04290546) | Dana-Farber Cancer Institute | 2020-07-20 |
| Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer (NCT04375384) | Wake Forest University Health Sciences | 2020-07-01 |
| Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer (NCT04220775) | M.D. Anderson Cancer Center | 2020-03-18 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC (NCT03813836) | University College, London | 2019-07-05 |
| Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat (NCT03823131) | Chase Heaton, MD | 2019-05-02 |
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer (NCT03468218) | Emory University | 2018-09-18 |
| Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer (NCT03521570) | Emory University | 2018-06-28 |
| Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT03522584) | University of Washington | 2018-05-17 |
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma (NCT03422536) | University of Arizona | 2017-12-05 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278) | Rutgers, The State University of New Jersey | 2017-10-03 |
| CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (NCT02955290) | Roswell Park Cancer Institute | 2016-12-22 |
| A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT01602315) | Novartis Pharmaceuticals | 2012-11-12 |
| Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (NCT01468896) | National Cancer Institute (NCI) | 2011-10-26 |
| Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (NCT00494182) | M.D. Anderson Cancer Center | 2007-04-25 |